Storia in 1 fonti

LifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)

In a report released today, Gaurav Maini from LifeSci Capital maintained a Buy rating on Sionna Therapeutics, Inc., with a price target of $60.0...

Raccontata da